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CObjective: This study updated a 2001 decision economic model that
used indirect data and confirmed its findings by developing a new cost-
effectiveness model by using now available head-to-head data. The
models compared olanzapine with ziprasidone in the treatment of
schizophrenia in theUnited States.Methods: Adecision analyticmod-
eling approach was used to estimate annual health-care costs and
health outcomes, incorporating events such as response, relapse, and
suicide. Patients without response to first-line treatment switched to
the other comparator. Decision tree probabilities were extracted from
head-to-head studies and other published clinical literature. Direct
health-care costs and quality-adjusted life-years (QALYs) were esti-
mated on the basis of resource use and utility weights for initial and
relapse episodes, maintenance therapy, and extended episodes of ill-
ness. Disutilities associated with treatment-emergent adverse events
were included. Results: Consistent with the 2001 model, this model
ound that first-line treatment with olanzapine is associated with O
o rep
mpan
al So
oi:10.1016/j.jval.2011.08.1741ewer hospital days, fewer days with extrapyramidal symptoms, and
igher QALYs than is first-line treatment with ziprasidone. Total costs
ere lower for the olanzapine pathway ($70,232–$72,776 vs. $73,086–
73,310 in the Positive and Negative Syndrome Scale analysis) due to
he cost savings associatedwith reduced health-care resource use. The
ncremental cost per QALY gained indicated that the olanzapine path-
ay dominated the ziprasidone pathway. Conclusions: Decision ana-
ytic models should be continuously assessed against new data. This
ase study shows that incorporating new data confirmed results of a
reviously published model in which olanzapine was associated with
etter expectedhealth outcomes and lower total health-care costs than
as ziprasidone.
eywords: cost-effectiveness, economic model, olanzapine, schizo-
hrenia.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
At the point of launch of new pharmaceutical products, decision
makers are forced to evaluate each product’s efficacy, safety, and
tolerability profile to determine approval status for the submitted
indication as well as its economic profile for reimbursement. De-
cision analytic models are often used to help inform various
health-care policy makers on better ways to allocate limited re-
sources. Skepticism about potentially biased industry-sponsored
economic models, however, prevails [1]. Ideally, decision makers
would like to compare the new treatment against current stan-
dards of care and other treatments entering themarket around the
same time; however, limited head-to-head data make direct com-
parisons difficult in both the clinical and economic settings.
From the mid-1990s to early 2000s, many second-generation
(atypical) antipsychotics were introduced in the market for the
treatment of schizophrenia, an often severe and chronic neuro-
psychiatric disorder that is very costly in terms of total direct
health-care costs per patient [2,3] due primarily to the relapsing
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098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.nature of the illness and the need for costly psychiatric hospital-
izations [4].
Olanzapine and ziprasidone are among the atypical antipsychot-
ics. While olanzapine was launched in the United States in 1996,
ziprasidone was approved by the US Food and Drug Administration
in 2001. The individual phase 3 registration trials and other clinical
trials for olanzapine and ziprasidone—in 2001, when ziprasidone
was approved—were primarily against placebo or a first-generation
(typical) antipsychotic, haloperidol, making head-to-head compari-
sons of these two drugs difficult. Having no head-to-head informa-
tion on the efficacy of these products, an economic model was cre-
ated to assist formulary decision makers in the United States
determine which product produced the most benefit for the money
spent when making formulary adoption decisions [5]. In the 2001
analysis, indirect comparisons weremade by combining the clinical
data from the individual drug trials, some limited head-to-head
safetydataononesafetyparameter, andcost information fromother
published literature into a single economic model by careful use of
the data andmodeling assumptions.
The original 2001 decision model presented its findings as pre-
liminary in nature and concluded that “clinical head-to-head trials
ort.
y, Lilly Corporate Center, Indianapolis, IN 46040, USA.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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comparative clinical effectiveness, tolerability, and cost-effective-
ness of olanzapine in relation to ziprasidone” that “would provide
decision-makers withmore precise information that could be eas-
ily incorporated into the existing or more elaborate models to up-
date the results” [5]. Since 2001 several randomized head-to-head
trials have been conducted that included both olanzapine and
ziprasidone as treatment comparators in the treatment of schizo-
phrenia. These comparative trials were sponsored by Eli Lilly and
Company, the manufacturer of olanzapine, by Pfizer, the manu-
facturer of ziprasidone, and by independent researchers. We set
out to update the previous model to confirm the model conclu-
sions and test the robustness of the indirect comparisons by using
data from head-to-head randomized trials. We additionally con-
ducted a literature search to determine whether newer informa-
tionwas available regarding othermodel inputs andwhether clin-
ical guidelines had changed since the previous analysis. This
article describes a case study of the update and confirmation pro-
cess and the results of the updated economic comparison.
Methods
Alexeyeva et al. [5] describe the original model, which was pro-
grammed in Microsoft Excel, in detail. Briefly, the pharmacoeco-
nomic analysis follows schizophrenia patients for 1 year after
treatment initiation by using a decision tree structure (Fig. 1). Dur-
ing the year, patients may experience response to the initial drug
treatment (olanzapine or ziprasidone). If patients do not respond,
they may switch to a second-line treatment (olanzapine, ziprasi-
done, or risperidone) and have another chance of treatment
response. In addition, patients who do not respond to either first-
Fig. 1 – Model structure. Decision tree probabilities are aline treatment or second-line treatment are switched to a third-line treatment that is assumed to be clozapine. Finally, patients
who respond to either the first-line treatment or the second-line
treatment have a chance of relapse during the year and may at-
tempt and/or complete suicide. Using this structure, the direct
medical costs attributable to schizophrenia and the drug treat-
ments considered by the model are estimated from the perspec-
tive of a US third-party payer.
To update the economicmodel, the following stepswere taken:
1. Identify new modeling techniques that are relevant to the
analysis;
2. Identify head-to-head data for inclusion;
3. Analyze and synthesize data; and
4. Update model programming and data input parameters and
perform a quality check.
These steps are described in detail in the following subsections.
Identify new modeling techniques
Quality-adjusted life-years (QALYs) and the incremental cost per
QALY gained are expected to be a part of model outcomes and are
required by some health technology assessment agencies for re-
imbursement approval. Therefore, relevant utility weights were
included in the model health states and disutilities attributed to
treatment-related adverse events.
Probabilistic sensitivity analyses (PSAs) are often requested
and/or required by health technology assessment agencies for drug
submissions. A PSA was programmed into the Excel model using
Visual Basic for Applications to run the Monte Carlo simulation.
Finally, meta-analysis is a statistical technique that can com-
bine point estimates of efficacy from several trials into a single
measure using a series of weights and calculations. A random
ble in the clinical inputs section of the text and Table 2.vailaeffects meta-analysis using the methods of Einarson [6] to incor-
rward
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input for the model was conducted.
Identify up-to-date data
A series of targetedMedline literature searches were conducted to
identify published randomized, head-to-head trials that included
both olanzapine and ziprasidone. All searches included the MeSH
main heading term “schizophrenia” combined with free text
terms and Medline limits targeting the major components of in-
puts for themodel. The targeted literature searcheswere compiled
and abstractswere reviewed to identify articles for full-text review
(see Appendix Table 1 in Supplemental Materials at doi:10.1016/
j.jval.2011.08.1741 for full search strategy and results).
Analyze and synthesize data
Clinical inputs
Ten primary studies were identified for further review and poten-
tial inclusion into the meta-analysis [7–16].
As described in the model description section, the efficacy
measure of interest to themodel was patient response to the drug
treatment. In schizophrenia trials, response is often measured by
using the Brief Psychiatric Rating Scale (BPRS), the Positive and
Negative Syndrome Scale (PANSS), or both. As such, it was deter-
mined that these two measures were the most appropriate out-
comes to assess response, as costs and utility weights identified
were based on response to treatment.
From the 10 potential studies identified, only 3 [7,11,14] re-
ported PANSS response, BPRS response, or both in their publica-
tion or included requested data from themanufacturer. The other
trials had response estimates that were either not reported or not
consistent with what was needed for the model. Table 1 provides
a summary of the three included trials.
It can be seen that the three studies are all slightly different in
length (6, 24, and 28 weeks), patient population, and response out-
comes reported. We assumed that a trial length greater than 6
weeks does not affect the probability of response. This rationale is
based on figures from Breier et al. [7] and Simpson et al. [14] that
show little change in total score in PANSS and BPRS levels after
weeks 5 to 6 of treatment. Therefore, it is assumed that response
would occur at the same point regardless of trial length, and the
estimates of timing of the three trials were comparable. In regard
to the patient populations in the trials, Breier et al. [7] were the
most inclusive as both inpatients and outpatients were random-
ized. The populations in Kinon et al. [11] (outpatients) and Simp-
Table 1 – Summary of studies reporting PANSS or BPRS res
Study Trial design Comparato
Breier et al.
[7]
28-week, multicenter, randomized,
double-blind, parallel design
Olanzapine (n 27
ziprasidone (n
Kinon et al.
[11]
24-week, multicenter randomized,
double-blind, parallel design,
fixed dose
Olanzapine (n 20
ziprasidone (n
Simpson et
al. [14]
6-week, multicenter, randomized,
double-blind, parallel design,
flexible dose
Olanzapine (n 13
Ziprasidone (n
BPRS, Brief Psychiatric Rating Scale; LOCF, last observation carried foson et al. [14] (inpatients) could be considered subsets of the pop-ulation included in Breier et al. [7]. Therefore, tomeasure response
over a broad population, we included all three studies in themeta-
analysis. Sensitivity analyses were performed that examined the
effect of including/excluding each of the studies in themeta-anal-
ysis as well as using the results of each individually in the model.
Themeasure of response selected for themeta-analysis was at
least 30% improvement from baseline to end point (trial comple-
tion) in PANSS, BPRS, or both by using the last observation carried
forward as this was the most consistently reported outcome.
Simpson et al. [14] did not report PANSS; therefore,wewere unable
to include this study in the meta-analysis for PANSS response.
However, it was included in the BPRSmeta-analysis. Table 2 sum-
marizes the response outcomes from each individual trial and the
random effects meta-analyses conducted. Overall, heterogeneity
was detected between trials in all analysis. Forest plots for all anal-
yses are available in the appendix (Appendix Fig. 1A–D in Supple-
mental Materials at doi:10.1016/j.jval.2011.08.1741). These out-
comes serve as the model inputs for the probability of response.
Another clinical data component that was shown to be a major
driver of costs and outcomes in the original model was relapse rate.
Only one of the three identified head-to-head studies reported re-
lapse-related information. Breier et al. [7] report that 14.6% of olan-
zapine-treated patients and 25.3% of ziprasidone-treated patients
experience an exacerbation of symptoms (defined as 20% or more
decline in PANSS total score and decrease of 1 ormore points on the
Clinical Global Impression-Severity illness score after week 8 of the
trial). Exacerbation of symptomshaspreviously beenused as aproxy
for relapse and was used as such in the updated model as well.
Cost inputs
Our search of the cost literature found that current cost-effective-
ness studies were continuing to use the same sources of schizo-
phrenia-related costs from the originalmodel [5,19–21]. Therefore,
with the exception of drug costs, cost sources were unchanged;
however, costs were inflated to 2009 US dollars by using the med-
ical component of the Consumer Price Index [22].
The amount and probability of medical resources used (e.g.,
hospital days, outpatient visits, group therapy, and residential
treatment) were kept constant from the original Alexeyeva et al
model [5] and are shown in Table 3. Table 4 summarizes the up-
dated unit cost inputs and data sources used in the current anal-
ysis. Drug costs were updated to the most recent Wholesale Ac-
quisition Costs from the Red Book [25]. Assumptionsweremade by
using the data reported in clinical publications for average dose
per day, which is used in combination with drug acquisition costs
se.
Patient population Response outcomes reported
Inpatients and outpatients LOCF 30% improvement from
baseline to end point in total
scores of PANSS (Breier et al.,
[7]) and BPRS (Eli Lilly and
Company, unpublished data,
2009)
Outpatients with prominent
depressive symptoms
LOCF 30% improvement from
baseline to end point in total
scores of PANSS and BPRS (Eli
Lilly and Company,
unpublished data, 2009)
Acutely ill inpatients LOCF 20%, 30%, and 40%
improvements from baseline
to end point in BPRS total
score
; PANSS, Positive and Negative Syndrome Scale.pon
rs
7);
271)
2);
192)
3)
136)to calculate an average cost per day. The mean modal doses for
e and
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ported to be 15.27 and 115.96 mg/d, respectively. For simplifica-
tion, a 15-mg/d dose is assumed for olanzapine and a 120-mg/d
dose is assumed for ziprasidone. An average dose for risperidone
is assumed to be 4 mg/d as a 4-mg dose has been shown to be
compared with 15 mg of olanzapine in clinical trials such as Con-
ley and Mahmoud [27]. Finally, Mauskopf et al. [19] report the av-
erage dose for clozapine to be 304 mg/d. For simplification, a 300-
mg/d dose for clozapine is assumed.
Utility weight inputs
The model was updated to include utility weights as a measure of
societal health state preferences. The updated model contains
Table 2 – Observed response from individual studies and c
Analysis study Respons
PA
Olanzapin
Original model (Alexeyeva et al., [5])
Beasley et al. [17], Keck et al. [18] —
Individual studies
Breier et al. [7] 58.6% (0.030
Kinon et al. [11] 28.8% (0.032
Simpson et al. [14] NR
Random effects meta-analysis
Breier et al. [7] and Kinon et al. [11] 43.7% (0.148
Breier et al. [7] and Simpson et al. [14] UE
Breier et al. [7], Kinon et al. [11], and Simpson
et al. [14]
UE
Kinon et al. [11] and Simpson et al. [14] UE
BPRS, Brief Psychiatric Rating Scale; NR, not reported; PANSS, Positiv
Table 3 – Resource utilization.
Resource use per cycle % using ser
Initial episode and relapse episode
Hospital days 100.00%
Additional hospital days due to switch 100.00%
Outpatient psychiatrist visits 100.00%
Non-MD group therapy 100.00%
Initial episode only
Residential treatment days 33.00%
Partial treatment days 33.00%
Outpatient treatment days 33.00%
Relapse episode
Residential treatment days 50.00%
Partial treatment days 50.00%
Outpatient treatment days 0.00%
Maintenance cycle
Residential treatment days 2.50%
Partial treatment days 2.50%
Outpatient treatment days 5.00%
Outpatient psychiatrist visits 65.00%
Non-MD group therapy 65.00%
Nonresponsive patients (extended episode)
Hospital days
Acute hospital 100.00%
State psychiatric hospital 100.00%
Residential home care 100.00%
Outpatient services 100.00%utility weight estimates for the time period patients are treated
during an initial episode (cycle) or a relapse episode (cycle) and
treated during a maintenance cycle. Utility weights for initial and
relapse episodes are further subdivided into whether treatment is
provided in an inpatient hospitalization setting or is nonhospital
based. In addition to these utility weights, the updatedmodel con-
tains disutilities for common adverse events associated with the
model comparators.
We derived utility weights to match the treatment settings de-
scribed above and the disutilities by using the data reported in
Lenert et al. [28]. The incidence of common adverse events attrib-
utable to the model comparators is displayed in Table 5, while
ined meta-analysis results.
asure (30% improvement from baseline to trial end point)
mean (SE) BPRS, mean (SE)
Ziprasidone Olanzapine Ziprasidone
— 53.4% 48.8%
42.5% (0.0306) 76.9% (0.0258) 62.1% (0.0300)
19.6% (0.0296) 49.7% (0.0362) 38.0% (0.0363)
NR 40.0% (0.0438) 36.0% 0.0429
31.0% (0.1149) 63.4% (0.1356) 50.1% (0.1204)
UE 58.6% (0.1843) 49.2% (0.1303)
UE 55.70% (0.1190) 45.50% (0.0911)
UE 45.2% (0.0486) 37.2% (0.0277)
Negative Syndrome Scale; SE, standard error; UE, unevaluable.
Number of days Source(s)
22 Palmer et al. [20]
5 Alexeyeva et al. [5]
3 Palmer et al. [20]
6 Palmer et al. [20]
Palmer et al. [20]
49 Palmer et al. [20]
49 Palmer et al. [20]
Palmer et al. [20]
49 Palmer et al. [20]
49 Palmer et al. [20]
Palmer et al. [20]
65 Palmer et al. [20]
65 Palmer et al. [20]
1 Palmer et al. [20]
6 Palmer et al. [20]
22 Palmer et al. [20]
37 Mauskopf et al. [20]
Palmer et al. [20]
65.50 Mauskopf et al. [19]omb
e me
NSS,
e
1)
8)
9)vice125.30 Mauskopf et al. [19]
cost
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are summarized in Table 6.
The key model inputs for both the current model and the pre-
vious model are provided in Appendix Table 2 in order to clearly
identify what has been updated.
Probabilistic sensitivity analysis inputs
A PSA was undertaken to evaluate the impact of simultaneous vari-
ation in clinical outcome and resource utilization parameters on the
model results by using second-orderMonte Carlomethods. Beta dis-
tributions were used for model probabilities and utility weights.
Gamma distributions were used for health state costs. Standard er-
rorswere set to those calculated in themeta-analysis for response or
reported in the clinical publications for other model input parame-
ters where available. Where unavailable, standard errors were as-
sumed to be 10% of the mean reported value.
Update model programming and perform a quality check
The original model was updated to include a new input system that
allowed the selectionof trials tobe included in themeta-analysis and
the outcome onwhich to base themeta-analysis (PANSS or BPRS). In
Table 4 – Cost inputs and data sources.
Resource Unit cost ($)
Hospital day 898*
Residential treatment day 520*
Outpatient psychiatrist visit 91
Non-MD group therapy 73*
Partial treatment day 371*
Outpatient treatment day 116*
Suicide attempts/completion 7829*
Suicide legal costs 1755*
State psychiatric hospital day 567*
Residential home care day 567*
Drug cost per day
Olanzapine 19.50
Ziprasidone 15.09
Risperidone (generic) 2.38
Clozapine (generic) 3.67
Compliance 85%
Anticholinergic drug cost per day 0.99
* Inflated to 2009 US dollars using the medical component of the Con
the probabilistic sensitivity analyses estimated as 10% of the mean
Table 5 – Adverse event incidence.
Adverse event Incidence (%)
EPS symptoms
Olanzapine 17.0
Ziprasidone 19.0
Risperidone 29.0
Clozapine 10.0
Weight gain
Olanzapine 12.6
Ziprasidone 1.9
Risperidone 5.9
Clozapine 12.6
Hypotension (all) 1.0
EPS, extrapyramidal symptoms; SE, standard error.
* Standard error for use in the probabilistic sensitivity analyses estimatedaddition to updating othermodel inputs, a PSAwas added andutility
weights were incorporated into the Excel programming.
In order to ensure that the updated model was producing accu-
rate results and that errors were not introduced during the update
process, two typesofquality checkswereperformed.Thefirstquality
check was conducted by entering the input parameters from the
original model into the updated model and checking to make sure
that the results of the twomodelsmatched. This provided validation
that no errors were introduced into the components that were
shared between the twomodel versions.
The second type of quality check involved a thorough review of
the updated model inputs to ensure they were extracted properly
from their respective source publications, a check of all model
calculations, and a check of the Visual Basic for Applications code
that runs the PSA.
Results
The base-case analyses conducted were based on the meta-anal-
yses of the PANSS scale (PANSS analysis) and the BPRS scale (BPRS
analysis). For reference, the PANSS meta-analysis included data
Source
Palmer et al. [20]; The Essential RBRVS [21]
Palmer et al. [20]; NAPHS [23]
The Essential RBRVS [21]
Palmer et al. [20]; RFI [24]
Palmer et al. [20]; NAPHS [23]
Palmer et al. [20]; NAPHS [23]
Mauskopf et al. [19]
Mauskopf et al. [19]
Mauskopf et al. [19]
Mauskopf et al. [19]
Breier et al. [7]; Red Book for Windows [25]
Breier et al. [7]; Red Book for Windows [25]
Assumed 4-mg dose; Red Book for Windows [25]
Mauskopf et al. [19]; Red Book for Windows [25]
Mauskopf et al. [19]; Tran et al. [26]
Alexeyeva et al. [5]; Red Book for Windows [25]
r Price Index (US Department of Labor [22]). Standard error for use in
.
Source
7* Mauskopf et al. [19]
9* Alexeyeva et al. [5]; FDA [39]
9* Mauskopf et al. [19]
0* Mauskopf et al. [19]
Breier et al. [7]
8 Breier et al. [7]
Lieberman et al. [12]; Breier et al. [7]
Bitter et al. [29]
1*sumeSE
0.01
0.01
0.02
0.01
0.20
0.00
0.02
0.02
0.00as 10% of the mean cost.
dated
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ata from these two studies and from Simpson et al. [15] as well.
Deterministic results
In both the PANSS and BPRS analyses, the olanzapine pathways
resulted in fewer hospital days, fewer days with extrapyramidal
symptoms, and greater QALYs than did the ziprasidone pathways.
These results and also a breakdown of costs by cost category are
displayed in Table 7. Overall, among the cost categories, inpatient
costs contributed the most to costs being between 77% and 80% of
total costs. Outpatient costs were the next largest cost component
followed by antipsychotic drug costs, suicide costs, and anticho-
linergic drug costs.
Also, in the PANSS analysis, the 1-year direct medical costs for
starting treatment with olanzapine were $72,776 when patients
were switched to ziprasidone if no response and $70,232 when
switched to risperidone. Starting treatment with ziprasidone re-
sulted in costs of $73,682 with a switch to olanzapine and $73,459
with a switch to risperidone. Thus, starting treatment with olan-
zapine resulted in cost savings of $906 compared with starting
treatment with ziprasidone when both are switched to the other
and cost savings of $3,227 when both are switched to risperidone.
In the BPRS analysis, the 1-year directmedical costs for starting
treatment with olanzapine were $68,840 when patients were
switched to ziprasidone if no response and $68,176when switched
to risperidone. Starting treatment with ziprasidone resulted in
costs of $70,075 with a switch to olanzapine and $71,505 with a
switch to risperidone. Thus, starting treatment with olanzapine
resulted in cost savings of $1,235 compared with starting treat-
ment with ziprasidone when both are switched to the other and
cost savings of $3,329 when both are switched to risperidone.
Overall, antipsychotic drug costs for the olanzapine pathways
were higher than for the ziprasisone pathways in all analyses ow-
ing to the higher drug acquisition cost for olanzapine. These price
differences, however,were overcomeby other directmedical costs
Table 6 – Utility weights and disutilities.
Health state Utility weight
Mean
Controlled symptoms (maintenance) 0.880 0.
Uncontrolled symptoms (initial
episode, relapse episode,
extended episode)
Acute hospitalization 0.570 0.
Nonhospital treatment 0.745 0.
Adverse event disutilities
EPS symptoms 0.076 0.
Weight gain 0.031 0.
Hypotension 0.058 0.
EPS, extrapyramidal symptoms.
* Standard error for use in the probabilistic sensitivity analyses estimbeing higher for ziprasidone pathways than for olanzapine path-ways because of the higher efficacy in both the PANSS and BPRS
analyses for olanzapine.
Given the cost savings of the olanzapine pathways and the
better patient outcomes (hospital days, extrapyramidal symptom
days, and QALYs), all incremental cost-effectiveness ratios (ICERs)
calculated (incremental cost per hospital day avoided, extrapyra-
midal symptom day avoided, and QALY gained) resulted in the
olanzapine pathways dominating (less costly and more effective)
the ziprasidone pathways.
Sensitivity analyses
One-way sensitivity analysis
A one-way sensitivity analysis was conducted and indicated that
the model was robust to alternate sources of input parameters
(generally ranging from 20% of the baseline value). The most
sensitive parameter was the source of response selected for the
model. We conducted a series of scenario analyses specifically
examining how response was estimated. This included varying
the studies included in the meta-analysis and looking at how re-
sults faired by using results from each study independently. In
each of these scenarios, the olanzapine pathways remained cost
saving to the ziprasidone pathways and in all but one scenario the
ICER dominated the ziprasidone pathway. Incremental costs and
QALYs from each of these scenarios are summarized in Figures 2
and 3.
Probabilistic sensitivity analysis
Results of 10,000 second-orderMonte Carlo simulations of the PSA
are summarized in the form of cost-effectiveness scatter plots. In
the PANSS analysis, olanzapine, compared with ziprasidone, had
an incremental cost per QALY gained less than or equal to the
generally accepted cost-effectiveness threshold of $50,000 per
QALY gained, when both are switched to the other, in 87.6% of the
simulations performed (Fig. 4).When switching to risperidone, the
Source/assumption
Weighted mean standard gamble utility for state 1 (mild)
from Lenert et al. [29]
Average of weighted mean standard gamble utilities for
states 4 (severe type I [0.63]), 5 (severe type II [0.65]),
6 (severe type III [0.53]), 7 (severe type IV [0.62]), and
8 (extremely severe [0.42]) from Lenert et al. [28]
Average of weighted mean standard gamble utilities for
states 2 (moderate type I [0.75]) and 3 (moderate type II
[0.74]) from Lenert et al. [28]
Average of mean disutilities from the subtractive model
for adverse event disutilities from Lenert et al. [28] for
tardive dyskinesia (0.095), pseudo-Parkinsonism
(0.074), and akathisia (0.059)
Mean disutility from the subtractive model for adverse
event disutilities from Lenert et al. [28] for weight gain
Mean disutility from the subtractive model for adverse
event disutilities from Lenert et al. [28] for orthostatic
hypotension
as 10% of the mean cost.SE
088*
057*
074*
011
008
010results were similar, showing that the olanzapine pathway had an
ab
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61V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 5 5 – 6 4incremental cost per QALY gained less than or equal to $50,000 in
81.7% of the simulations compared with the ziprasidone pathway
(see Appendix Fig. 2A in Supplemental Materials at doi:10.1016/
j.jval.2011.08.1741). In addition, the olanzapine pathways domi-
nated the ziprasidone pathways in 83.1% of the simulations when
switching to each other and 54.7% of the simulations when
switching to risperidone.
The BPRS analysis showed similar results to the PANSS analy-
sis. Olanzapine had an incremental cost perQALY gained less than
or equal to $50,000 compared with ziprasidone, when both are
switched to the other, in 95.5% of the simulations performed (see
Appendix Fig. 2B in Supplemental Materials at doi:10.1016/
j.jval.2011.08.1741). When switching to risperidone, the olanzap-
ine pathway had an incremental cost per QALY gained less than or
equal to $50,000 in 86.9% of the simulations compared with the
ziprasidone pathway (see Appendix Fig. 2C in Supplemental Ma-
terials at doi:10.1016/j.jval.2011.08.1741). Finally, the olanzapine
pathways dominated the ziprasidone pathways in 90.6% of the
simulations when switching to each other and 59.3% of the simu-
lations when switching to risperidone.
Exploratory sensitivity analysis
Changes in metabolic parameters, including new-onset diabetes,
have been reported during treatmentwith atypical antipsychotics,
including olanzapine and ziprasidone [30]. Because of this in-
creased class risk, it is important to understand how the manage-
ment of diabetes in this population impacts the cost-effectiveness
of olanzapine. To further understand the impact of this medical
condition, we conducted an exploratory sensitivity analysis
around this risk.
Currently, there is no consensus around the incidence of
diabetes risk potentially associated with schizophrenia treat-
ments. A meta-analysis has shown that second-generation an-
tipsychotics have a slightly higher increased risk of diabetes
than do first-generation antipsychotics [31]. Within the second-
generation antipsychotics, Lambert et al. [30] found diabetes
incidence to be similar between olanzapine and other antipsy-
chotics (risperidone, quetiapine, clozapine, and haloperidol) in
a large study of US Veterans. However, other analyses have
found olanzapine to have an increased risk of diabetes than
other atypicals [12,32,33]. To investigate the potential effect of
incident diabetes on model results, we conducted two explor-
atory sensitivity analyses. In both analyses, the development of
diabetes was associated with a disutility of 0.151 [34].
In the first exploratory analysis, we attributed an annual
diabetes incidence of 5.5% to all atypical antipsychotics in-
cluded in the model based on the number of diabetes cases
reported for patients treated with olanzapine (1,098) and the
total number of olanzapine-treated patients (19,780) in the Lam-
bert analysis.
In the second exploratory analysis, we assumed that olanzap-
ine had an increased risk of diabetes over that of the other atypical
antipsychotics modeled. We estimated this risk by estimating the
risk of diabetes for risperidone in the Lambert et al. [30] analysis to
be 5.2% (also assumed 5.2% for clozapine and ziprasidone) and
applied an estimated hazard ratio of 1.71 [32] for olanzapine, re-
sulting in an estimated incidence of diabetes of 8.9%.
In both exploratory analyses, the olanzapine pathways re-
mained dominant by incurring less total costs and accruing more
QALYs than the ziprasidone pathways.
Discussion
This article describes a case study of the process and results of up-
dating and confirming an economic model when better data (i.e.,
head-to-head) becomeavailable. Based on theupdated input param-
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62 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 5 5 – 6 4eters, first-line treatment with olanzapine is cost saving compared
with starting treatment with ziprasidone. This was shown to be the
case across awide variety ofmethods to examine the efficacy of both
products and switching scenarios to second-line treatments if re-
sponse was not experienced. The olanzapine pathways dominated
the ziprasidone pathways in all but one of a multitude of base-case
and scenario analyses. In addition, the vast majority of the simula-
tions performed in the PSA indicated that the olanzapine pathways
were cost-effective compared with the ziprasidone pathways.
The original model [5] also showed the olanzapine pathway to
be cost saving in comparison with the ziprasidone pathway. The
savings were approximately $200 in 2001 US dollars. Our analysis
calculated savings between $890 and $3500 depending on the
treatment pathway and analysis (PANSS vs. BPRS) examined in
2009 US dollars. Themajority of the savings differences are attrib-
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t al. [11] and Simpson et al. [14].utable to the increase in incremental efficacy between olanzapine
and ziprasidone seen in the head-to-head trials versus those trials
used in the original model.
This article discusses cost-effectiveness practices that have
evolved since the original analysis. Completed today, the original
analysis would likely have taken a different form as well. Current
standard practices such as network meta-analyses could be used
to strengthen indirect analysis of clinical data. Furthermore, when
the direct head-to-head trials were completed their clinical data
could have been added to the network analysis so that all available
clinical data could be used in the analysis. Value of information
analysis also could have been completed to determine the benefit
of conducting the head-to-head comparisons between olanzapine
and ziprasidone before trial initiation.
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63V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 5 5 – 6 4Although we updated the model with the best available data,
several limitations to the updated process and the resultantmodel
should be noted. First, while we consider our literature search to
be thorough and inclusive of the major clinical trials including
both olanzapine and ziprasidone in the last decade, it was not
conducted by using a full systematic method. Despite this limita-
tion, it is likely that systematic methods and inclusion of addi-
tional databases would not have resulted in additional data points
for the meta-analyses.
Next, of the clinical studies that were identified for full-text
review from our targeted literatures searches, themajority did not
report outcomes in amanner that would lend them to inclusion in
the meta-analysis. Thus, the meta-analysis was limited to three
studies for the BPRS analysis and two for the PANSS analysis.
Given that, the meta-analysis was not quite as robust and inclu-
sive of head-to-head studies as we had initially hoped. However,
results from the excluded studies indicate that their inclusion
likely would not have changed the conclusions and results of the
model. Overall, both olanzapine and ziprasidone were similar
among the effects measured. It is important to note that Lieber-
man et al. [12] showed that compared with ziprasidone, the olan-
apine treatment group had much lower annual risk of hospital-
zation for exacerbation of schizophrenia (risk ratio of 0.29 for
lanzapine; 0.57 for ziprasidone). A lower rate of relapse, as mea-
ured by psychiatric inpatient hospitalization, was also found
n The Ziprasidone Observational Study of Cardiac Outcomes
ZODIAC) [35], sponsored by Pfizer, the manufacturer of ziprasi-
one. These results are not unlike the differential risk of relapse
sed in the present cost-effectiveness model.
Another study limitation is the inclusion of a limited number of
treatment-emergent adverse events and exclusion of treatment-
emergent diabetes in the base-case analysis. We conducted two
exploratory sensitivity analyses regarding the possibility of simi-
lar risk and increased risk of diabetes for olanzapine. Neither anal-
ysis changed the conclusions of the model. A limitation of the
exploratory analyses is that we did not include the costs associ-
atedwith diabetes. However, prior research on the cost of diabetes
among patients with schizophrenia [36] and cost-effectiveness
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Fig. 4 – Olanzapine to ziprasidone versus ziprasidone to olan
PANSS Analysis. CE, cost-effectiveness; PANSS, Positive andmodels in the antipsychotic treatment of schizophrenia [37,38]have found the cost of this potential adverse event to be relatively
small compared with the total treatment cost of schizophrenia.
Finally, of the studies that were included in themeta-analyses,
the patient populations varied widely. Because of differences in
patient severity, the response estimateswere also greatly variable.
To control for these differences, we performed a wide variety of
scenario analyses examining various possible combinations of
studies in the meta-analysis and results of individual studies
through themodel. In all but one scenario, the results of themodel
were similar to those of the base-case analyses.
Strengths of the model include the use of data from random-
ized head-to-head clinical trials and the use of state-of-the-art
modeling techniques that helped to confirm model robustness
and conclusions. In addition, the wide variety of scenario anal-
yses conducted help demonstrate that different assumptions
surrounding clinical efficacy sources would produce similar re-
sults.
We believe that this publication serves as a good example of
the process of updating an economic model when new data be-
come available to confirm earlier findings. Results of the model
were shown to be robust to numerous scenarios performed and
also confirm the results of the original model that was based on
indirect efficacy data. In both the original model and the updated
model, olanzapine was shown to be a cost-saving option for first-
line schizophrenia treatment comparedwith ziprasidone. This in-
dicates that, while imperfect, economic models that are built on
limited indirect data and reasonable assumptions can be used as a
proxy for economic decisions until more direct data are available.
Source of financial support: Eli Lilly and Company.
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Supplemental material accompanying this article can be found in
the online version as a hyperlink at doi:10.1016/j.jval.2011.08.1741
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